Protective MHC-I dependent immune responses require an overlap between repertoires of proteins directly presented on target cells and cross-presented by professional antigen presenting cells (APC), specifically dendritic cells (DCs). How stable proteins that rely on DRiPs for direct presentation are captured for cell-to-cell transfer remains enigmatic. Here we address this issue using a combination of in vitro and in vivo approaches involving stable and unstable versions of ovalbumin model antigens displaying DRiP-dependent and -independent antigen presentation, respectively. Apoptosis, but not necrosis of donor cells was found associated with robust p62dependent global protein aggregate formation and captured stable proteins permissive for DC crosspresentation. Potency of aggregates to serve as antigen source was directly demonstrated using polyglutamine-equipped model substrates. Collectively, our data implicate global protein aggregation in apoptotic cells as a mechanism that ensures the overlap between MHC-I epitopes presented directly or cross-presented by APC and demonstrate the unusual ability of DC to process stable protein aggregates.
Introduction
The immune system evolved to sense and eliminate infected and transformed cells, taking advantage of peptide presentation on MHC class I (MHC-I) to trigger antigen-specific cytotoxic T lymphocytes (CTL) (1). MHC-I is expressed by all nucleated cells and generally presents peptides originating from intracellular proteins (2, 3) . The MHC-I peptide repertoire is hence dynamic, reflecting the constant alteration of the intracellular proteome. This 'direct presentation' pathway samples the general peptide pool generated by proteasomal degradation, a peptide subset that is actively transported into the endoplasmic reticulum (ER) by the ATP-dependent transporter associated with antigen processing (TAP) (4) . In the ER, peptides are loaded onto newly synthesized MHC-I molecules in a facilitated manner, and peptide-MHC-I complexes are transported for presentation to the cell surface.
MHC-I peptides can originate from various sources: short-lived proteins that are directed to the proteasome by regulated ubiquitination (5) and retirees of long-lived proteins (6) . A third major MHC-I peptide source is believed to consist of defective ribosomal proteins (DRiPs) (7, 8) .
DRiPs arise through faulty initiation from downstream codons, premature termination, short protein segments produced by pioneer translation rounds during nonsense mediated decay (NMD), mRNA quality control (QC) and out-of-frame translated protein segments (9) (10) (11) (12) .
At the cell surface, MHC-I peptide complexes are constantly surveyed by CD8 + T lymphocytes carrying epitope-specific T cell receptors (TCRs) (13) . Once complexes are recognized, CD8 + T cells are activated and acquire cytotoxicity that allows them to eliminate peptide-presenting specific target cells (14) . The initiation of CTL responses against infected cells requires 'priming' by professional antigen presenting cells (APC) through an antigen crosspresentation pathway (15, 16) (Carbone et al., 1998; Jung et al., 2002) , which is restricted to a BatF3-dependent CD8 + dendritic cell (DC) subset (DC1) (17, 18) . Cross-presentation requires endocytosis of cellular material, protein transport from the lysosome to the cytoplasm and proteasomal processing (19, 20) . In contrast to direct presentation, cross-presentation hence relies in addition to proteasome activity (21) on prior proteolysis in the lysosome (22, 23) . Polypeptides are delivered to the proteasome from the endocytic compartments, perhaps by forming ER/endosome mixed vesicles (24) . Yet, the exact cascade of events that interconnects cytosolic and endocytic proteolysis for cross-presentation remains incompletely understood (25) (26) (27) (28) (29) .
Efficient protective MHC-I dependent immune responses require the overlap between the antigenic MHC-I repertoires that are presented directly on infected cells and cross-presented by the APC (30) . Biochemical mechanisms that ensure this repertoire overlap are poorly understood.
Specifically, it is unclear how extremely stable proteins, such as virus-derived structural peptides (7) , that rely for direct presentation on DRiPs, are captured for cross-presentation, as DRiPs are unavailable for cell-to-cell transfer.
Here we show that both stable and unstable variants of the model antigen ovalbumin (RFP-Ova & Ova-RFP) contribute antigenic epitopes for direct presentation in DRiP-dependent and DRiP-independent manner, respectively. Despite their distinct stabilities, both fusion proteins also performed equally well in cross-presentation of apoptotic cells, including pattern and magnitude of elicited in vivo responses, as well as their ability to induce functional T cell cytotoxicity. Nonselective aggregation that was induced in apoptotic, but not necrotic cells, prior to their engulfment by DCs, was found to constitute a major antigenic source for MHC-I cross presentation. Congruent with this notion, polyQ (94Q)-Ova derivatives, engineered to aggregate independently of apoptosis, served as potent long-lasting source for cross-presentation. Collectively, our data underscore protein aggregation as a major factor that contributes to the repertoire overlap between direct and cross-presented MHC-I antigens of stable cellular proteins.
Results

DRiP -dependent and -independent MHC class I antigen presentation of OVA model antigens.
To study mechanisms regulating the overlap between direct and indirect MHC-I presentation we engineered two proteins of distinct stability that share identical primary sequence; both substrates included the intact ovalbumin (Ova) sequence fused to a stable globular monomeric red fluorescent protein (RFP), either at its N' or C' terminus (RFP-Ova and Ova-RFP, respectively). Studying proteasomal processing of these fusion molecules in EL4 cells, we previously demonstrated that ovalbumin was degraded only when its N-terminus was accessible (Ova-RFP) (31) . When RFP was attached to the ovalbumin N' terminus (RFP-Ova), the cellular abundance of the protein increased relative to Ova-RFP, despite similar mRNA levels ( Figure 1A and 1B). This difference was attributed to proteasomal degradation, as Ova-RFP was stabilized in the presence of the proteasome inhibitor (Velcade) ( Figure 1A ).
Cells expressing either RFP-Ova or Ova-RFP were examined for their steady state H-2K b MHC-class I levels and their specific MHC/peptide complex display ( Figure 1C ). The immunodominant Ova MHC-I epitope in C57BL/6 mice (SIINFEKL) was efficiently presented on EL4 cells expressing either RFP-Ova or Ova-RFP, as indicated by antibody surface staining for H-2K b /SIINFEKL complexes (32) ( Figure 1C ). Sensitivity of presentation to Velcade, but resistance to the lysosomal inhibitor Bafilomycin A (BafA) confirmed that SIINFEKL presentation was proteasome-dependent for both Ova-RFP and RFP-Ova expressing cells ( Figure 1D ). Notably, H-2K b surface levels were moderately affected by Velcade treatment, but not BafA (Supplementary Figure S1 ), and the effect did not reach significance. All flow cytometry analyses were controlled for cell viability using Annexin V and DAPI staining (Supplementary Figure S2 ). Taken together, these findings suggest that Ova epitopes detected on cells expressing RFP-Ova derive mainly from ribosome-associated quality control (QC), rather than the pool of stable RFP-Ova molecules. To further substantiate this notion, RFP-Ova and Ova-RFP expressing EL4 cells were incubated with or without the translation inhibitor cycloheximide (CHX) and H-2K b /SIINFEKL levels were examined. CHX treatment resulted in a larger decrease of surface complexes in cells expressing stable RFP-Ova compare to cells expressing the unstable Ova-RFP ( Figure 1E ). These data are consistent with a higher contribution of ribosome-associated degradation, i.e. DRiPs, as a source of MHC-I epitopes of stable proteins than less stable proteins.
We conclude that DRiP-dependent (RFP-Ova) and -independent (Ova-RFP) model antigens constitute a valuable system to elucidate mechanisms ensuring effective cross-presentation of epitopes that depend for direct MHCI presentation on QC processes.
Cross-presentation efficacy of stable and unstable proteins match the efficiencies observed in direct presentation.
Following CD8 + T cell differentiation into effectors, CTLs recognize and eliminate infected or transformed cells that display cognate antigen epitopes. Induction of effector functions requires specialized APCs, such as classical XCR1 + DCs (cDC1), that ingest apoptotic infected or transformed cells and shuttle proteins of the latter into their own MHC-I pathway (17) . To test the efficiency by which RFP-Ova and Ova-RFP are captured for cross-presentation, we applied in vitro and in vivo T cell activation assays. The magnitude of in vitro T cell activation directly correlated with the level of H-2K b /SIINFEKL complexes presented on cells expressing either RFP-Ova or Ova-RFP (Supplementary Figure S3) . The B3Z T cell hybridoma line expressing -galactosidase under control of the IL-2 promoter showed a small difference in SIINFEKL presentation and the related T cell response in favor of RFP-Ova, which did not reach statistical significance (Supplementary Figure S3 ).
To measure in vivo T cell responses to cells expressing the OVA variants, we engrafted C57BL/6 wild type (WT) animals with H-2K b /SIINFEKL-reactive T cells isolated from TCR transgenic OT-I mice (33) . Grafted cells expressed an allotypic marker (CD45.1) to distinguish them in the recipients and were labeled with the intracellular dye CarboxyFluorescein Succinimidyl Ester (CFSE) to monitor their proliferation (34) . Engrafted mice were immunized with apoptotic cells expressing the Ova derivatives ( Figure 2A ). Cells expressing either of the different OVA constructs or no Ovalbumin, displayed comparable apoptotic cell percentages (Supplementary Figure S4 ). Flow cytometric analysis of lymph node and spleen cell preparations of the mice for OT-I T cells revealed robust T cell proliferation in response to both RFP-Ova and Ova-RFP immunizations, as indicated by CSFE dilution ( Figure 2C ). However, as opposed to the above in vitro experiment (Supplementary Figure S3 ), we observed a significant statistical difference between animals immunize with the two constructs in favor of RFP-Ova ( Figure 2C ).
Development of the cDC1 DC subset dedicated to cross-presentation depends on the transcription factor BATF3 (18) . To investigate if cDC1 are also required for the T cell priming observed in our system, we generated bone marrow (BM) chimeras by transplanting irradiated WT animals with Batf3-deficient (Batf3 -/-) BM (18) . Absence of cDC1 from spleens of [Batf3 -/-> WT] chimeras was confirmed by flow cytometric analysis (Supplementary Figure S5 ). As opposed to [WT > WT] controls, proliferation of adoptively transferred OT-I cells was completely abrogated in immunized Batf3 KO chimeras ( Figure 2D ), establishing that processing of the Ova derivatives and cross-presentation of their SIINFEKL epitopes is executed predominantly by cDC1s.
For immune surveillance, MHC-I directed immune responses are meant to remove cells decorated with pathogen-or transformation-associated non-self epitopes. To test whether the immunizations with apoptotic cells expressing the Ova derivatives result in cytotoxicity, we used an in vivo killing assay (35) . Immunization with apoptotic cells expressing the stable RFP-Ova that displayed superior presentation level of SIINFEKL and T cell stimulation also generated the most efficient in vivo killing activity ( Figure 2E , Supplementary Figure S6 ). In contrast, immunization with Ova-RFP expressing apoptotic cells induced significantly less cytotoxicity ( Figure 2E ). Taken together, for the antigenic system we tested including stable and unstable model proteins, the efficiency of direct presentation matched the efficiency of cross-presentation, which is an important factor in inducing the ultimate protective CTL response.
Global protein aggregation during apoptosis captures the stable cellular steady state proteome.
As shown above, direct MHC-I presentation of RFP-Ova relies on DRiPs or other QC pathways.
Arguably, these mechanisms provide insufficient protein material for transfer and crosspresentation by APCs. To directly address this issue, we monitored the abundance and the distribution of both Ova derivatives following apoptosis induction. Protein distributions in supernatant and pellet fraction were assessed as described previously (36) . Briefly, cells were lysed in the presence of 1% NP-40 and the lysate was overlaid on a 20% glycerol cushion. Samples were centrifuged at 100,000g for 45 min at 4°C. As expected, in untreated cells, both the stable longlived RFP-Ova derivative and the short-lived Ova-RFP derivative were detected almost exclusively in the supernatant ( Figure 3A ). In contrast, upon apoptosis induction, most of the proteins were detected in the insoluble pellet fraction, suggesting that apoptosis is accompanied by aggregate formation ( Figure 3A ). Notably, aggregation was not ensued upon cell synchronization, but only following treatment with etoposide (Supplementary Figure S7 ). Lamin B1 was used to assess the supernatant / pellet separation ( Figure 3A ), as lamin B1, a major component of nuclei, is known to appear in the insoluble fractions (37, 38) . Notably, lamin B1 is processed upon apoptosis by caspase 7 and thus appeared truncated upon apoptosis providing a convenient additional internal control (39) (40) (41) (42) .
To quantify the extent of aggregation we performed a multispectral imaging flow-cytometry We next tested if aggregate formation is uniquely associated with apoptosis, or also triggered by necrosis. Apoptotic and necrotic RFP-Ova expressing cells (induced by etoposide and heat shock respectively) were identified by AnnexinV (AV) and DAPI staining. Apoptotic cells demonstrated 25-30% of AV + DAPIand AV + DAPI + populations. In contrast, necrotic cells did not comprise AV + DAPIevents (0.62%) and the majority of the cells were AV + DAPI + (86%) ( Figure   4A ), corroborating an earlier report (44) . ImageStream analysis of the two populations for RFP levels and extent of aggregate formation revealed that global RFP fluorescent signals were similar in both populations ( Figure 4B ). In contrast, the fluorescent signal appeared diffused in necrotic cells, while accumulated in aggregates in apoptotic cells ( Figure 4C and Supplementary Figure S8 ).
In line with this observation, high BDI values were only detected in the double positive AV + DAPI + apoptotic cells population ( Figure 4D ). DNA condensation in the cells was monitored by 'area threshold and contrast parameters' ( Figure 4E ). Apoptotic nuclei yielded small, fragmented, highly textured nuclear images with Draq5 dye localized to small punctate regions of the fragmented nucleus (45) . In contrast, such high contrast nuclear staining was absent from the necrotic cell preparation. The distinction between apoptosis and necrosis was also verified biochemically. As demonstrated above, lamin B1 is processed upon apoptosis ( Figure 3A ) (42) . In contrast, processing of lamin B1 was not detected in the necrotic cells preparation ( Figure 4F ). Taken together our findings suggest that in our system, apoptotic cell death, but not necrosis, is associated with global cellular protein aggregation.
p62 is involved in apoptosis related aggregates formation.
p62 was recently shown to be required for aggregate formation upon proteasomal inhibition (46) .
To test if p62 also contributes for the non-selective apoptosis-related aggregate formation we report here, we first verified that p62 is also required for Velcade-dependent aggregate accumulation in RFP-Ova expressing 39.5 cells. Specifically, we analyzed aggregate formation in cells in which p62 expression was impaired by siRNA ( Figure 5A ). As seen in Figure 5B , amounts of RFPcontaining aggregates, generated upon proteasomal inhibition, dramatically decreased, when p62 levels were reduced by siRNA (the efficiency of the sip62 is demonstrated in Supplementary Figure   S9 ). Velcade-dependent aggregates co-localized with p62. Reduction of p62 levels also correlated with diminished aggregation and a more diffused RFP signal for apoptosis-mediated aggregation ( Figure 5B ). Notably, both Velcade-induced and apoptosis-related aggregates co-localized with p62. In further support of an involvement of p62 in apoptosis-associated aggregate formation, both p62 transcripts, as well as cellular p62 protein levels were found elevated in early apoptosis ( Figure   5C ). Taken together these findings underscore p62 as an important factor in apoptosis-related aggregation.
Dendritic cells are endowed with the capacity to process polyQ aggregates and retrieve antigens for cross-presentation.
To directly evaluate if aggregates can serve as source for cross-presentation, we took advantage of an Ova derivative that is fused to RFP on both termini (RFP-Ova-RFP) and was previously shown to have a very short half-life (31) . This version of Ova, when delivered in apoptotic cells to mice did neither elicit T cell proliferation nor killing activity ( Figure 6A and B) .
To test if aggregate formation could render the protein immunogenic, we equipped the RFP-Ova-RFP molecule with an aggregation-prone polyglutamine (PolyQ) encoding sequence. PolyQ stretches in proteins cause the accumulation of nonreversible deleterious aggregates and are associated with neuronal and muscular degenerative diseases (47, 48) . Long PolyQ stretches are particular strong inducers of aggregation; we hence added 94 glutamine residues to the N-terminus of RFP-Ova-RFP (94Q-RFP-Ova-RFP). Immunization of mice with apoptotic cells expressing this PolyQ derivative resulted in a strong T cell proliferation and efficient CTL responses ( Figure 6A and B). This suggests that promoting the aggregation of a very labile protein can serve as a strategy to induce cross-presentation and trigger cytotoxic immunity.
The fact that addition of the polyQ stretch rendered 94Q-RFP-Ova-RFP immunogenic suggests that polyQ aggregates can act as efficient protein source. Alternatively, immunogenicity could have resulted from a dynamic equilibrium between the polyQ-decorated fusion proteins en route to aggregation, rather than from the aggregates themselves. Moreover, some RFP-Ova-RFP degradation fragments may have re-dissolved and served as antigen source (49) . Based on the fact that polyQ aggregates are endowed with extremely long-term stability, while the soluble intermediates are short-lived, we addressed this possibility by generating a TET-regulated Figure S11 ).
Next, CFP-Ova-RFP and 94Q-CFP-Ova-RFP cells (7 days following Dox withdrawal) were triggered for apoptosis and used to challenge animals (as described in Figure 2 ). Significant T cell proliferation was detected only when the 94Q-CFP-Ova-RFP expressing cells were used as immunogen ( Figure 6E ). To further test the potency of aggregates as a source of antigens in cross presentation, we monitored the level of direct presentation in cells expressing 94Q-CFP-Ova-RFP immediately following induction. As evident, most of the cells were CFP + RFP + and presented SIINFEKL on surface MHC-I (Supplementary Figure S12 ). However, 72h following Dox withdrawal, i.e. in absence of new translation, only aggregates remained in these cells, and as a consequence direct SIINFEKL presentation, was lost (Supplementary Figure S12B) . In contrast, cross presentation remained efficient, as seen in the in vivo read out ( Figure 6E ). This was the case, although the cells had undergone 3-4 cell divisions and the amount of aggregates was hence 10 times diluted (Supplementary Figure 12A ). This finding directly demonstrates the potency of aggregates in cross-presentation.
Taken together, these results directly demonstrate the ability of DC, and specifically cDC1, to process aggregates and support a mechanism whereby stress-related aggregation upon apoptosis is an important and potent protein source for cross-presentation.
Discussion
Cross-presentation by DCs is critical to raise cytotoxic T cell immunity against infected and transformed cells. How the diverse pool of cellular proteins is efficiently channeled for MHC-I presentation in DCs remains incompletely understood. Here we provide evidence that apoptosis results in the formation of aggregates that can be efficiently used as antigen source for crosspresentation by DCs.
Following viral infection, pathogen-derived antigens are efficiently presented on MHC-I of infected cells (51) ; this is despite the fast kinetics of presentation and the fact that a significant fraction of these antigens originates from stable viral proteins. This observation led to the proposal that QC mechanisms, such as DRiPs, are a major source for direct MHC-I presentation of viral proteins and presumably other stable protein (7) . To study how the epitopes contributed by DRiPs to MHCI direct presentation are captured and presented in cross-presentation, we used engineered chimeric protein constructs, which harbor a dominant ovalbumin H-2K b epitope (6, 52, 53) . By flipping the position of a stable globular domain juxtaposed to Ova, we created versions that are either rapidly turned-over or stable (Ova-RFP, RFP-Ova) (31) . Direct MHC-I presentation of the short-lived version (Ova-RFP) was influenced by its turnover rate. Presentation of the stable protein (RFP-Ova) was a DRiP-dependent process, corroborating the notion that DRiPs are a crucial source for MHC-I presentation of epitopes originating from stable proteins. Furthermore, our findings suggest that peptides that are generated in the course of 'translation QC' are more efficiently processed and potentially loaded onto MHC-I. This might indicate a tighter ER retrograde transport of proteasomal products generated upon ribosomal QC degradation (54) . Taken together this scenario would encode a biological bias favoring QC-associated mechanism, such as DRiPs, in MHC-I presentation of stable proteins. Notably, this would affect for instance the presentation of viral proteins, which are frequently exposed to multiple steps of translation-associated QC cycles, ensuring the proper glycosylation and assembly (55) .
In the process of cross-presentation/cross-priming, presented peptides are derived from an exogenous source (25) , rendering DRiPs irrelevant. In support of this notion, proteasomal degradation products of donor cells do not contribute to MHC-I cross-presentation in the recipient APCs (56) . The latter is consistent with the role of cross-presentation in directing immune responses to non-self antigens, avoiding the dominating self repertoire associated with the high flux of proteasomal degradation of self short-lived proteins (SLIPs) (57) and QC rejects.
In view of the importance of repertoire overlap of direct and cross-presentation for effective immune responses (30) , it is unclear how extremely short-lived entities, such as DRiPs, can be captured by DCs, as only limited amounts of them are available for cell-to-cell transfer. Our data suggest that global nonselective aggregation is a significant biological process that enables capturing the steady state abundance of the cellular stable proteome engulfed by DCs, in a manner conducive for presentation.
We propose that apoptosis entails global protein aggregation, which ensures that the crosspresented protein spectrum mirrors the contribution of DRiPs and QC-related epitopes in MHC-I direct presentation. Our findings suggest that this mechanism enforces representation of antigens originating from stable proteins at the expense of very short-lived proteins, thereby directing immune responses towards relevant antigens, including viral proteins in the case of infected cells.
In addition, involvement of protein aggregation is consistent with earlier studies demonstrating that stable proteins are the major contributors to cross-presentation (56, (58) (59) (60) (61) . This is also in agreement with the proposed role of heat shock proteins (HSPs) in cross-presentation (62), as these serve as potential promoters and stabilizers of aggregates. In fact, molecular chaperones were implicated as a mechanism to facilitate the transfer of antigenic peptides derived from stable proteins to cross-presentation (63, 64) . In support of this model, various HSPs, including hsp70, hsp90, and grp94 gp96, isolated from tumors, as well as infected or transfected cells yield antigenic peptides (63) . Notably, the function of aggregates in cross-presentation also highlights a potential role for autophagy in the processing of aggregates. This notion is further supported by the role of p62 in apoptosis related aggregation, as p62 may serve for targeting of the aggregates to autophagy upon intake by DCs.
To directly assess if aggregates can serve as a significant source for cross-presentation, we utilized polyQ to drive aggregation of our proteins of interest. PolyQ expansion-related pathologies result from faulty proteins that harbor abnormally long stretches of glutamine residues. The extent of aggregation and the severity of the related disease directly correlate with the length of the polyQ stretch, where 94Q is in the very upper range of the scale (65, 66) . Using this system we demonstrated directly that aggregates serve as efficient source for antigens in cross-presentation and that DCs are endowed with a robust ability to process even extreme aggregates.
Notably, global aggregation was not observed in heat-induced necrotic cell death suggesting that aggregates are not an exclusive source of antigens for cross-presentation, but that there are multiple ways for APCs to acquire intact antigens from their environment. As phagocytes, APCs efficiently internalize dying cells and their debris, as well as shed exosomes, all of which contain intact antigens (28, (67) (68) (69) . It has also been reported that DCs can actively ingest pieces of antigen-bearing cells (70) . In support of this notion, intact protein antigens, both in particulate form and, less efficiently, in soluble form, can be cross-presented on MHC class I by professional APC, at least in in vitro systems (60) . In this respect, intake of aggregates as cellular debris or within exosomes (71) would be advantageous as the mass / volume ratio of relevant material to be used in cross-presentation is higher compared with intake of soluble proteins in more diluted form. Either way, the fact that cross-presentation relies on both lysosomal and proteasomal processing (25) is beneficial, as lysosomes were shown to process polyQ-related aggregates. This leaves the trafficking of the aggregates to the lysosome as a potentially limiting factor (72), and highlights the relevance of p62 as a potential lysosomal targeting factor of apoptosis-related aggregates in DC.
Interestingly, a functional role for aggregates in DC, in the context of APC capacity, was already noted in prior studies (73) (74) (75) . In these studies, DC aggresome-like induced structures (DALIS) were found to facilitate MHC-I cross-presentation of exogenous (non-self) antigens by diverting self-ubiquitinated proteins (including self-DRiPs) to transient aggregates. Although related, these structures are distinct from the aggregates in the current study, which are rather stable, produced in the donor cells and in contrast to DALIS serve as major antigen source for crosspresentation. Taken together with our current findings, we conclude that DC have evolved to use aggregation both to reduce the self MHC-I antigens load upon immunological challenge, as well as to select relevant antigens in target cells for cross-presentation.
Future detailed studies of the mechanisms that control aggregation in the donor cells and de-aggregation and processing in the APC are important to understand the pathways underlying the generation of CTL-mediated immune responses and exploit them for therapeutic vaccination strategies. Furthermore, the robust and unique ability of DC to process polyQ aggregates, even when aggregation is driven by a long polyQ stretch (94Q), as illustrated here in vivo, demonstrated for the first time an efficient physiological capacity of DC to process polyQ aggregates, probably relying on lysosomal catabolism (76) . This might suggest a potential role for the immune system in clearing aggregates that should be further studied and potentially could be exploited for therapy.
Methods
Mice C57BL/6 (CD45.2) WT mice were purchased from Harlan (Rehovot, Israel). OT-I T cell receptor (TCR) transgenic mice (33) were bred in the animal facility of the Weizmann Institute. BM chimeras were generated using WT and BatF3 KO BM (kindly provided by Kenneth Murphy) (18). 
Generation of EL4 and 39.5 cells expressing ovalbumin variants fused to RFP
Ova fused to RFP was cloned into pMIG, a retroviral expression vector, which harbors an IRES-GFP element. Viruses were generated in 293T cells by triple transfection with Env and Gag-pol encoding vectors, as described (78) . Transduced EL4 or 39.5 cells were sorted to GFP-positive to 100% purity by FACS (Aria, BD) and cultured similarly to parental EL4 cells. 
Monitoring the levels of H-2K b /SIINFEKL complex on the EL4 cell surface
10 6 EL4 cells of interest were washed with FACS washing buffer (PBS, 0.5% BSA, 0.1%NaN 3 ) and incubated for 60 min on ice with 25D1.16, a mouse monoclonal antibody, which recognizes the H-2K b /SIINFEKL complex (32) . Cells were then washed three times with the buffer and incubated on ice with Alexa Flour 647-conjugated anti-mouse polyclonal antibody for 60 min (Molecular Probes). Consequently, the cells were resuspended in PBS and analyzed by FACS (BD biosciences). Mean fluorescence intensity (MFI) was calculated, using FACSdiva software (BD biosciences). EL4 cells were treated with 5µM Velcade (Bortezomib, Selleck Chemicals, 179324-69-7) to inhibit the proteasome activity, and 50µg/ml chyclohexamide (CHX) (Sigma, C7698-1G) to inhibit the ribosome activity.
Peptide stripping by acid wash
To remove MHC class I bound peptides from the cell surface, cells were washed with citrate phosphate buffer, pH 3.0 (0.263 M citric acid and 0.123 M disodium phosphate), as described (79) .
Briefly, cells were washed twice with PBS and then incubated for 1 minute with 0.3 ml citrate phosphate buffer at room temperature. Afterwards, cells were washed twice with RPMI 1640 medium, supplemented with 10% fetal bovine serum, 2 mM Glutamine, 50 units/ml Penicillin, 50 µg/ml Streptomycin, 1x nonessential amino acids and 1 mM Sodium Pyruvate. Subsequently, cells were resuspended in fresh medium and analyzed by FACS, or further incubated with the relevant reagents.
B3Z T cell activation assay
Sixty thousand B3Z cells, a LacZ-inducible CD8 + T cell hybridoma specific for the SIINFEKL/H- OD595 was determined using a Varioskan Microplate reader.
Adoptive cell transfer
CD8 + T cells (isolated from 10 weeks old female OT-I mice) were positively selected from CD45.1 + donor spleens using anti-CD8α beads (Miltenyi biotech). OT-I T cell proliferation was assessed by staining with 5µM carboxyfluorescein diacetate succimidyl ester (CFSE; (34)) for 8 min at RT in RPMI medium without serum. CFSE labeling was quenched by adding two volumes of cold FCS and 5 min incubation on ice. Cells were washed in RPMI medium and 1X10 6 cells were transferred intravenously to recipient naïve C57BL/6 WT mice. Probe dilution was quantified 5 days later using flow cytometry.
Apoptosis induction and antigen administration
cells expressing either ovalbumin variants fused to RFP or no vector (Empty cells) were
incubated for 12 hours with 500 µM Hydroxyurea (SIGMA, H8627-1G) to induce cell synchronization. Apoptosis was induced with 100 µM Etoposide (SIGMA, E1383-25MG) for an additional 12 hours. Thereafter, the cells were washed with PBS, and 1X10 6 apoptotic cells were injected intravenously to the C57BL/6 WT recipient mice, 24 hours following OT-I CD8 + T cells transfer.
Necrosis induction and AnnexinV/DAPI labeling
39.5 cells expressing ovalbumin variants fused to RFP were collected and incubated for 5 minutes at 65°C. Then cells were washed with PBS and incubated for 15 min at room tempature with 510 bright field annexinV; 5 µl in 100 µl binding buffer (50 mM Hepes, 700 mM NaCl, 12.5 mM CaCl2, pH 7.4). Following an additional wash with PBS Draq5 and DAPI were added to the cells which were analyzed by ImageStream.
In vivo cytotoxicity assay
The in vivo killing assay was performed as described before (35) . 7 days following apoptotic cells injection, splenocytes were isolated from WT CD45.1 + mice. Half of the cells were pulsed with 10µg/ml SIINFEKL peptide for 2h at 37°C. Unpulsed and pulsed cells were stained with 0.5 or 5 µM CFSE, respectively, and a 1:1 mixture of the cells was transferred to immunized C57BL/6 WT mice. The differential clearance of both target cell populations was evaluated using flow cytometry 24 hours later. Specific killing was defined as . This value was normalized to
the average specific killing of control mice, immunized with apoptotic cells harboring empty vector.
Western Blot analysis
Total cellular proteins were prepared in NP-40 buffer (25 mM Tris, pH 7.4, 150 mM NaCl, 1%
IGEPAL CA-630 [Sigma, I8896]), the extracts were centrifuged for 20 min at 21,000 x g and lysates were separated to supernatant and pellet. Sup protein concentration was determined using Pierce BCA protein Assay Kit (Thermo scientific, 23225). Twenty µg protein was loaded from sup and the corresponding amount was loaded from pellet. Proteins were separated on gradient 7%-15% SDS-PAGE gel. The membrane was blocked in 10% BSA for 30min at room temperature.
After blocking, the membrane was incubated with appropriate primary antibody at 4°C overnight or at room temperature for 3 h. Then the membrane was washed with PBS-TWEEN20 (PBS supplemented with 0.5% TWEEN-20, [Sigma, P1379]), and incubated with the secondary antibody (goat-anti-mouse or goat-anti-rabbit) at room temperature for 45 min. Finally, the membrane was washed 3 times and the specific proteins were visualized using the Enhanced ChemiLuminescence (ECL) detection system (Biological Industries 20-500-120). Antibodies used for western blot in this study: home-made rat α-RFP antibody, mouse α-actin (Santa cruze sc-376421) and rabbit αlamin B1 (Cell Signaling #12586).
Multispectral imaging flow-cytometry (Imagestream) analysis
Untreated cells and cells following induction of apoptosis were imaged using multispectral imaging flow cytometry (ImageStreamX flow cytometer; Amnis Corp). For multispectral imaging flow cytometry, approximately 3x10 4 cells were collected from each sample and data were analyzed using image analysis software (IDEAS 6.0; Amnis Corp). Images were compensated for fluorescent dye overlap by using single-stain controls. Cells were gated for single cells using the area and aspect ratio features, and for focused cells using the Gradient RMS feature, as previously described Similar results were obtained when RFP-Ova expressing cells were used (data not shown). 
